Evidence map›Paper›PMID 31962002›Full record

Trial reportCancer medicine2020

Patient-reported symptom burden as a prognostic factor in treatment with first-line cetuximab plus chemotherapy for unresectable metastatic colorectal cancer: Results of Phase II QUACK trial.

Akira Ooki, Satoshi Morita, Shigeyoshi Iwamoto, Hiroki Hara, Hiroaki Tanioka, Hironaga Satake, Masato Kataoka, Masahito Kotaka, Yoshinori Kagawa, Masato Nakamura and 10 more

Open access · goldAbstract readClinical Trial, Phase IIMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Cancer medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 9 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 19 institutions in 1 country.

Akira OokiDepartment of Gastroenterological Chemotherapy, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.ORCID 0000-0001-7618-5775
Satoshi MoritaDepartment of Biomedical Statistics and Bioinformatics, Kyoto University, Kyoto, Japan.
Shigeyoshi IwamotoCancer Center, Aichi Medical University, Nagakute, Japan.
Hiroki HaraDepartment of Gastroenterology, Saitama Cancer Center, Saitama, Japan.
Hiroaki TaniokaDepartment of Clinical Oncology, Kawasaki Medical School, Kurashiki, Japan.
Hironaga SatakeCancer Treatment Center, Kansai Medical University Hospital, Osaka, Japan.
Masato KataokaDepartment of Surgery, National Hospital Organization Nagoya Medical Center, Nagoya, Japan.
Masahito KotakaGastrointestinal Cancer Center, Sano Hospital, Kobe, Japan.
Yoshinori KagawaDepartment of Surgery, Kansai Rosai Hospital, Amagasaki, Japan.
Masato NakamuraComprehensive Cancer Center, Aizawa Hospital, Matsumoto, Japan.
Tatsushi ShingaiDepartment of Surgery, Osaka Saiseikai Senri Hospital, Suita, Japan.
Masashi IshikawaDepartment of Surgery, Shikoku Central Hospital, Shikokuchuo, Japan.
Yasuhiro MiyakeDepartment of Surgery, Osaka Minato Central Hospital, Osaka, Japan.
Takeshi SutoDepartment of Surgery, Yamagata Prefectural Central Hospital, Yamagata, Japan.
Yojiro HashiguchiDepartment of Surgery, Teikyo University School of Medicine, Tokyo, Japan.
Taichi YabunoDepartment of Surgery, Yokohama Municipal Citizen's Hospital, Yokohama, Japan.
Junichi SakamotoTokai Central Hospital, Kakamigahara, Japan.
Akihito TsujiDepartment of Medical Oncology, Kagawa University, Kita, Japan.
Masahiko AndoDepartment of Advanced Medicine, Nagoya University Hospital, Nagoya, Japan.
Kensei YamaguchiDepartment of Gastroenterological Chemotherapy, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
Japanese Foundation For Cancer Research · JPAichi Medical University · JPAizawa Hospital · JPKagawa University · JPKansai Medical University · JPKansai Rosai Hospital · JPKawasaki Medical School · JPKyoto University · JPNagoya University Hospital · JPNational Hospital Organization · JPOsaka Hospital · JPSaiseikaisenri Hospital · JPSaitama Cancer Center · JPSanno Medical Center · JPShikoku Central Hospital of the Mutual Aid Association of Public School Teachers · JPTeikyo University · JPTokai Central Hospital · JPYamagata Prefectural Central Hospital · JPYokohama Municipal Citizen's Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIt remains unclear whether patients' self-perceptions of symptoms at baseline clinically impact the prognostic relevance, treatment efficacy, or toxicity profiles in metastatic colorectal cancer (mCRC) patients treated with the first-line cetuximab and standard chemotherapy.

methodsThe data were collected from a prospective trial that assessed the relationships between quality of life (QOL), treatment efficacy, and adverse events (AEs).

resultsThe analysis of 137 mCRC patients revealed a significant association between the presence of baseline tumor-related symptoms and a lower overall survival (OS) compared to the absence of symptoms (HR, 2.49; 95% CI, 1.37-4.62; P = .003). The asymptomatic responders had favorable outcomes compared to the symptomatic nonresponders (2-year OS rates: 83.6% and 35.9%, respectively), while the symptomatic responders had similar outcomes to the asymptomatic nonresponders. The median postprogression survival differed significantly: 10.2 months for the symptomatic patients and 15.9 months for the asymptomatic patients (HR, 2.29; 95% CI, 1.25-4.29, P = .008). The objective response rates and patient toxicity profiles were similar irrespective of the severity of baseline symptoms.

conclusionBaseline symptoms were associated with worse OS but not with impaired treatment efficacy or more frequent AEs in mCRC patients treated with cetuximab in addition to chemotherapy.

Indexed as

Patient Reported Outcome MeasuresQuality of LifeAgedAntineoplastic Combined Chemotherapy ProtocolsCetuximabColorectal NeoplasmsDrug-Related Side Effects and Adverse ReactionsFemaleHumansKaplan-Meier EstimateMaleMiddle AgedPrognosisProgression-Free SurvivalProspective StudiesResponse Evaluation Criteria in Solid TumorsCetuximabcetuximabchemotherapycolorectal cancerquality of lifesymptom

Identifiers

PMID31962002
PMCPMC7050093
OpenAlexW3002583356

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.